HBV-KMT2B integrated human induced pluripotent stem cells (KMT2B-Int iPSCs) vs heterozygous mutated KMT2B iPSCs (KMT2B-HT iPSCs) vs homozygous mutated KMT2B iPSCs (KMT2B-KO iPSCs) vs their original iPSCs (KMT2B-WT iPSCs)

Transcriptional profiling of all KMT2B-WT, HT, KO, Int iPSCs. KMT2B-HT, KO, and Int iPSCs were generated by gene editing using CRISPR/Cas9 and Cre recombinase technologies. Transcriptional profiling of all KMT2B-WT, HT, KO, Int iPSCs. As the KMT2B-WT iPSCs, P11025 iPSCs were used, which were reprogrammed by the episomal vector from normal skin. KMT2B-HT, KO, and Int iPSCs were generated by gene editing using CRISPR/Cas9 and Cre recombinase technologies. KMT2B-HT iPSCs were used as control cell lines of KMT2B-Int iPSCs because KMT2B Int iPSCs were heterozygous KMT2B due to HBV integration. DNA sequences as results of gene editing such as integration of HBV sequences were determined by direct sequencing. Knockout of KMT2B also was confirmed by immunoblotting. All human iPSC lines were cultured and harvested before being fully confluent.